Other Events ·
On July 15, 2026, SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, initiated a Phase IIb clinical trial…
SPRCSciSparc Ltd.
On July 15, 2026, SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults. The randomized, double-blind, placebo-controlled trial evaluates the efficacy, safety, and tolerability of SCI-110, which combines dronabinol with palmitoylethanolamide. This follows a Phase IIa study that demonstrated an average tic reduction of 21% via the Yale Global Tic Severity Scale. Other trial sites include the Yale Child Study Center and Tel Aviv Sourasky Medical Center. The company operates in the pharmaceutical industry, focusing on developing cannabinoid-based treatments for central nervous system disorders.